title: [HER2 as a marker for guiding the choice of chemotherapy in breast cancer patients].
abstract: Patients diagnosed with local or locally advanced breast cancer are treated by a combination of surgery, radiation therapy and drug therapy (chemotherapy, biological and hormonal therapy). Recently, efforts have been made to customize drug treatment according to subgroups that will derive maximum benefit from a specific treatment. This goal is accomplished by the assessment of standard variables, among them specific receptors of the tumor and customization of treatment accordingly. For example, treatment with Herceptin is known to be beneficial only in patients with HER2 positive tumors. It has recently been suggested that this group also derives greater benefit from treatment with anthracyclines.
authors.affiliation: Hadassah Medical Center, Hadassah Ein Kerem, Jerusalem. aviadz@hadassah.org.il
authors.forename: Aviad
authors.initials: A
authors.lastname: Zick
authors.forename: Limor
authors.initials: L
authors.lastname: Appelbaum
mesh_terms: D018943:Anthracyclines / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D000068878:Trastuzumab
chemical_list: D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human